stoxline Quote Chart Rank Option Currency Glossary
  
Biodexa Pharmaceuticals Plc (BDRX)
0.7914  0.004 (0.51%)    07-23 16:00
Open: 0.785
High: 0.81
Volume: 594,524
  
Pre. Close: 0.7874
Low: 0.76
Market Cap: 0(M)
Technical analysis
2024-07-23 4:50:43 PM
Short term     
Mid term     
Targets 6-month :  1.51 1-year :  1.93
Resists First :  1.29 Second :  1.65
Pivot price 0.89
Supports First :  0.7 Second :  0.59
MAs MA(5) :  0.85 MA(20) :  0.89
MA(100) :  1.05 MA(250) :  2.62
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  8.9 D(3) :  14.1
RSI RSI(14): 41.7
52-week High :  9.64 Low :  0.67
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ BDRX ] has closed above bottom band by 24.0%. Bollinger Bands are 39.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.81 - 0.82 0.82 - 0.82
Low: 0.75 - 0.75 0.75 - 0.76
Close: 0.78 - 0.79 0.79 - 0.8
Company Description

Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the bio-delivery and biodistribution of medicines in Belgium and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTX223, a long-acting injectable formulations of biologic products, such as mAbs or other high molecular weight proteins. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Headline News

Tue, 23 Jul 2024
Biodexa Pharmaceuticals Secures $5M Funding - TipRanks

Tue, 23 Jul 2024
Announces Closing of $5.0 Million Registered Direct Offering and Concurrent Private Placement - StockTitan

Fri, 19 Jul 2024
Biodexa Pharmaceuticals sets $5 million offering - Investing.com

Fri, 19 Jul 2024
Biodexa Pharmaceuticals announces pricing of $5M registered direct offering (NASDAQ:BDRX) - Seeking Alpha

Tue, 16 Jul 2024
Biodexa Announces Phase 2a Study of Tolimidone in Type 1 Diabetes Approved by Health Canada - Markets Insider

Tue, 16 Jul 2024
How Is The Market Feeling About Biodexa Pharmaceuticals? - Quantisnow

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 9 (M)
Held by Insiders 1.17e+009 (%)
Held by Institutions 19.7 (%)
Shares Short 335 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -6.46e+006
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -2 %
Return on Assets (ttm) 843.3 %
Return on Equity (ttm) -51.4 %
Qtrly Rev. Growth 381000 %
Gross Profit (p.s.) -43.61
Sales Per Share -122.86
EBITDA (p.s.) 0
Qtrly Earnings Growth -10.5 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -7 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 0.74
Stock Dividends
Dividend 0
Forward Dividend 140930
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android